A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera
NCT ID: NCT05853445
Last Updated: 2024-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
467 participants
OBSERVATIONAL
2015-08-17
2023-05-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
NCT05421104
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
NCT05269771
Real-world Ruxolitinib Experience in PV
NCT06251102
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
NCT00595829
Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD
NCT04930445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JAK inhibitor naive
JAK inhibitor naive patients
Jakavi
Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
JAK inhibitor pre-treated
JAK inhibitor pre-treated patients (Jakavi® or any other JAK inhibitor for ≥3 months)
Jakavi
Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Jakavi
Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have been informed about this NIS and gave written consent
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Heidenheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Reutlingen, Baden-Wurttemberg, Germany
Novartis Investigative Site
Winnenden, Baden-Wurttemberg, Germany
Novartis Investigative Site
Aschaffenburg, Bavaria, Germany
Novartis Investigative Site
Augsburg, Bavaria, Germany
Novartis Investigative Site
Donauwörth, Bavaria, Germany
Novartis Investigative Site
Erlangen, Bavaria, Germany
Novartis Investigative Site
Herrsching am Ammersee, Bavaria, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Frankfurt (Oder), Brandenburg, Germany
Novartis Investigative Site
Landshut, Bvaria, Germany
Novartis Investigative Site
Brake, Lower Saxony, Germany
Novartis Investigative Site
Göttingen, Lower Saxony, Germany
Novartis Investigative Site
Twistringen, Lower Saxony, Germany
Novartis Investigative Site
Duisburg, North Rhine-Westphalia, Germany
Novartis Investigative Site
Bad Salzuflen, Northrhine Westfalia, Germany
Novartis Investigative Site
Iserlohn, Northrhine Westfalia, Germany
Novartis Investigative Site
Bautzen, Saxony, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Pirna, Saxony, Germany
Novartis Investigative Site
Lübeck, Schleswig-Holstein, Germany
Novartis Investigative Site
Erfurt, Thuringia, Germany
Novartis Investigative Site
Altötting, , Germany
Novartis Investigative Site
Augsburg, , Germany
Novartis Investigative Site
Bad Homburg, , Germany
Novartis Investigative Site
Bad Soden, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Bielefeld, , Germany
Novartis Investigative Site
Bottrop, , Germany
Novartis Investigative Site
Chemnitz, , Germany
Novartis Investigative Site
Cologne, , Germany
Novartis Investigative Site
Cologne, , Germany
Novartis Investigative Site
Dortmund, , Germany
Novartis Investigative Site
Dresden, , Germany
Novartis Investigative Site
Duisburg, , Germany
Novartis Investigative Site
Düren, , Germany
Novartis Investigative Site
Erfurt, , Germany
Novartis Investigative Site
Essen, , Germany
Novartis Investigative Site
Essen, , Germany
Novartis Investigative Site
Fürth, , Germany
Novartis Investigative Site
Gera, , Germany
Novartis Investigative Site
Goslar, , Germany
Novartis Investigative Site
Halberstadt, , Germany
Novartis Investigative Site
Halle, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hamelin, , Germany
Novartis Investigative Site
Hamm, , Germany
Novartis Investigative Site
Hamm, , Germany
Novartis Investigative Site
Hanover, , Germany
Novartis Investigative Site
Hanover, , Germany
Novartis Investigative Site
Heidelberg, , Germany
Novartis Investigative Site
Heilbronn, , Germany
Novartis Investigative Site
Hildesheim, , Germany
Novartis Investigative Site
Hildesheim, , Germany
Novartis Investigative Site
Hof, , Germany
Novartis Investigative Site
Idar-Oberstein, , Germany
Novartis Investigative Site
Kaiserslautern, , Germany
Novartis Investigative Site
Koblenz, , Germany
Novartis Investigative Site
Kronach, , Germany
Novartis Investigative Site
Leipzig, , Germany
Novartis Investigative Site
Lemgo, , Germany
Novartis Investigative Site
Loerrach, , Germany
Novartis Investigative Site
Lüdenscheid, , Germany
Novartis Investigative Site
Magdeburg, , Germany
Novartis Investigative Site
Marburg, , Germany
Novartis Investigative Site
Mayen, , Germany
Novartis Investigative Site
Memmingen, , Germany
Novartis Investigative Site
Minden, , Germany
Novartis Investigative Site
Moers, , Germany
Novartis Investigative Site
Mülheim, , Germany
Novartis Investigative Site
Münster, , Germany
Novartis Investigative Site
Naunhof, , Germany
Novartis Investigative Site
Nordhorn, , Germany
Novartis Investigative Site
Nuremberg, , Germany
Novartis Investigative Site
Nuremberg, , Germany
Novartis Investigative Site
Nuremberg, , Germany
Novartis Investigative Site
Offenburg, , Germany
Novartis Investigative Site
Oldenburg, , Germany
Novartis Investigative Site
Passau, , Germany
Novartis Investigative Site
Porta Westfalica, , Germany
Novartis Investigative Site
Potsdam, , Germany
Novartis Investigative Site
Rostock, , Germany
Novartis Investigative Site
Rostock, , Germany
Novartis Investigative Site
Rüsselsheim am Main, , Germany
Novartis Investigative Site
Schorndorf, , Germany
Novartis Investigative Site
Schöneck, , Germany
Novartis Investigative Site
Stolberg, , Germany
Novartis Investigative Site
Stuttgart, , Germany
Novartis Investigative Site
Stuttgart, , Germany
Novartis Investigative Site
Westerstede, , Germany
Novartis Investigative Site
Wiesbaden, , Germany
Novartis Investigative Site
Wittenberg, , Germany
Novartis Investigative Site
Wolfsburg, , Germany
Novartis Investigative Site
Würselen, , Germany
Novartis Investigative Site
Würzburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CINC424BDE12 that is getting linked from the Novartis Clinical Trials Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CINC424BDE12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.